Volume : 11, Issue : 01, January – 2024
Title:
OVERVIEW OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Authors :
Elham Yahya Baamer, Abdulaziz Mohammed F. Zaghwn, Khleel Adnan K. Alowyed, Einas Osman Abd Alla Osman, Wed Ziyad Alnajjar, Faraaz Adil Sanai, Hawra Mohamed Rabeea, Abdulla Faheem Abdulrahim, Faez Mohammadhasan A Zagzoug, Ayah Manaf A Albayat
Abstract :
Background: Chronic Obstructive Pulmonary Disease (COPD) is a complex disease influenced by both genetic and environmental factors, leading to irreversible lung damage, systemic complications, and a significant global health burden. Effective diagnosis, management, and adherence to treatment guidelines are essential to alleviate the burden on patients and improve outcomes.
Aim: The present study aims to review the update on Chronic Obstructive Pulmonary Disease.
Methods: Comprehensive research of COPD. PUBMED and Google Scholar search engines were the databases used for the search process, and articles were collected from 2013 to 2023. The terms used in the search were COPD, risk factors, Pathophysiology, Manifestations, Diagnosis, treatment, and Exacerbation.
Conclusion: COPD is a prevalent and progressive lung condition characterized by irreversible airflow obstruction, inflammation, and damage to lung tissue. The main subtypes are chronic bronchitis and emphysema. COPD is influenced by both genetic and environmental factors, with cigarette smoke being a primary risk factor. It is associated with systemic inflammation and comorbidities like cardiovascular diseases, diabetes, and muscle weakness. Viral infections, particularly influenza A viruses, can trigger acute exacerbations. The pathophysiology involves oxidative stress, altered immune response, and inflammation, leading to chronic bronchitis, emphysema, and small airway disease. Diagnosis includes spirometry, pulmonary function tests, and clinical factors, with various laboratory and imaging tools aiding in confirmation. Treatment strategies encompass pulmonary rehabilitation, pharmacologic therapies (bronchodilators, corticosteroids), surgical interventions, and oxygen therapy. Vaccinations are recommended, and careful management of exacerbations involves oxygen therapy, inhaled antibiotics, and corticosteroids. Smoking cessation is crucial, and newer therapies like stem cell-based treatments show promise.
Keywords: COPD, risk factors, Pathophysiology, Manifestations, Diagnosis, treatment, Exacerbation.
Cite This Article:
Please cite this article in press Elham Yahya Baamer et al., Overview Of Chronic Obstructive Pulmonary Disease., Indo Am. J. P. Sci, 2024; 11 (01).
Number of Downloads : 10
References:
1. Stockley RA. Chronic Obstructive Pulmonary Disease. Encyclopedia of Life Sciences2001.
2. Ogresta D. Komorbiteti u kroničnoj opstruktivnoj plućnoj bolesti: University of Zagreb. School of Medicine. Department of Internal Medicine; 2014.
3. Cho WK, Lee CG, Kim LK. COPD as a Disease of Immunosenescence. Yonsei Med J. 2019;60(5):407-13.
4. Korytina GF, Aznabaeva YG, Nasibullin TR, Kochetova OV, Khusnutdinova NN, Viktorova TV, et al. Gene-gene and gene-environment interactions of the inflammatory gene variants in the development of chronic obstructive pulmonary disease. GTM. 2022;1(1).
5. Rodriguez-Roisin R. Genes, Telomeres, Allergies and Biomarkers, Key Pathogenic Clues of Chronic Respiratory Diseases.
6. Rous JS, Lees PSJ, Koehler K, Buckley JP, Quirós-Alcalá L, Han MK, et al. Association of Occupational Exposures and Chronic Obstructive Pulmonary Disease Morbidity. Journal of Occupational and Environmental Medicine. 2023;65(7):e443-e52.
7. Fishwick D, Barber C, Wiggans R. Chronic Obstructive Pulmonary Disease and Work: The Continuing Narrative. Semin Respir Crit Care Med. 2023;44(3):378-84.
8. Rous JS, Lees PSJ, Koehler K, Buckley JP, Quirós-Alcalá L, Han MK, et al. Association of Occupational Exposures and Chronic Obstructive Pulmonary Disease Morbidity. Journal of Occupational and Environmental Medicine. 2023;65(7).
9. Sanz I, Tamames S, Rojo S, Justel M, Lozano JE, Disdier C, et al. Viral Etiology of Chronic Obstructive Pulmonary Disease Exacerbations during the A/H1N1pdm09 Pandemic and Postpandemic Period. Advances in Virology. 2015;2015:560679.
10. Aigoul Z, Rustem K. The Risk Factors of Frequent Exacerbations of COPD. In: Kian Chung O, editor. A Compendium of Chronic Obstructive Pulmonary Disease. Rijeka: IntechOpen; 2022. p. Ch. 4.
11. Arezina R, Chen T, Wang D. Conventional, Complementary and Alternative Medicines: Mechanistic Insights into Therapeutic Landscape of Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease. 2023:447-57.
12. Nucera F, Mumby S, Paudel KR, Dharwal V, Di Stefano A, Casolaro V, et al. Role of oxidative stress in the pathogenesis of COPD. Minerva Medica. 2022.
13. Antonyuk M, Mineeva E, Knyshova V, Urenko A, Vitkina T, Novgorodtseva T, et al. Features of immune response in different phenotypes of chronic obstructive pulmonary disease. Medical Immunology (Russia). 2022;24(1):109-20.
14. D’Anna SE, Maniscalco M, Cappello F, Carone M, Motta A, Balbi B, et al. Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease. Annals of Medicine. 2021;53(1):135-50.
15. Di Stefano A, Dossena F, Gnemmi I, D’Anna SE, Brun P, Balbi B, et al. Decreased humoral immune response in the bronchi of rapid decliners with chronic obstructive pulmonary disease. Respiratory Research. 2022;23(1):200.
16. van Eeden Stephan F, Hogg James C. Immune-Modulation in Chronic Obstructive Pulmonary Disease: Current Concepts and Future Strategies. Respiration. 2019;99(7):550-65.
17. Hao W, Li M, Zhang C, Zhang Y, Wang P. Inflammatory mediators in exhaled breath condensate and peripheral blood of healthy donors and stable COPD patients. Immunopharmacology and Immunotoxicology. 2019;41(2):224-30.
18. Yang A, Wu Y, Yu G, Wang H. Role of specialized pro-resolving lipid mediators in pulmonary inflammation diseases: mechanisms and development. Respiratory Research. 2021;22(1):204.
19. Nourian YH, Salimian J, Ahmadi A, Salehi Z, Karimi M, Emamvirdizadeh A, et al. cAMP-PDE signaling in COPD: Review of cellular, molecular and clinical features. Biochemistry and Biophysics Reports. 2023;34:101438.
20. Rahman I, MacNee W. Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol. 2012;12(3):256-65.
21. Warwick E, Scourfield A, Quint J. Systemic manifestations of chronic obstructive pulmonary disease. British Journal of Hospital Medicine. 2015;76(6):324-9.
22. Joshe MD, Emon NH, Islam M, Ria NJ, Masum AKM, Noori SRH, editors. Symptoms Analysis Based Chronic Obstructive Pulmonary Disease Prediction In Bangladesh Using Machine Learning Approach. 2021 12th International Conference on Computing Communication and Networking Technologies (ICCCNT); 2021 6-8 July 2021.
23. Celli BR, Fabbri LM, Aaron SD, Agusti A, Brook RD, Criner GJ, et al. Differential Diagnosis of Suspected Chronic Obstructive Pulmonary Disease Exacerbations in the Acute Care Setting: Best Practice. American Journal of Respiratory and Critical Care Medicine. 2023;207(9):1134-44.
24. Most JF, Possick J, Rochester CL. Systemic Manifestations and Comorbidities of Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine. 2014;21(4).
25. Keener A. Redefining the diagnostic criteria for COPD. Nature. 2020;581:S4+.
26. Kahnert K, Jörres RA, Behr J, Welte T. The Diagnosis and Treatment of COPD and Its Comorbidities. Dtsch Arztebl Int. 2023;120(25):434-44.
27. Talker L, Neville D, Wiffen L, Selim AB, Haines M, Carter JC, et al. Machine diagnosis of chronic obstructive pulmonary disease using a novel fast-response capnometer. Respiratory Research. 2023;24(1):150.
28. Tongdee S, Sawunyavisuth B, Sukeepaisarnjaroen W, Boonsawat W, Khamsai S, Sawanyawisuth K. [Not Available]. Drug Target Insights. 2021;15:21-5.
29. Wanot B, Stelmach A, Biskupek-Wanot A. Chronic obstructive pulmonary disease-criteria for diagnosis. Scientific Journal of Polonia University. 2018;27(2):128-35.
30. Kanwade AB, Bairagi V. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Using Electromyography (EMG): Academic Press; 2022.
31. Meghashri V, Raveesha A, Mehta C, Deepthi M. Correlation of Six Minute Walking Test, Sit to Stand Test and Pulmonary Function Test in Patients with Chronic Obstructive Pulmonary Disease. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. 2023;17(1):OC05-OC8.
32. Sementsov O, Stepanenko S. Radiation diagnostics of the state of ventilation and pulmonary circulation in patients with COPD. Modern medical technology. 2022(1):71-8.
33. Zhang Z, Wang J, Li Y, Liu F, Chen L, He S, et al. Proteomics and metabolomics profiling reveal panels of circulating diagnostic biomarkers and molecular subtypes in stable COPD. Respiratory Research. 2023;24(1):73.
34. van Dijk M. Treatment of severe COPD: physiology of lung volume reduction treatment and opioids for refractory dyspnea. 2022.
35. Boulos RT, Nemer LI, Mansour VJ, Abi Chahine NH. Treatment of a Chronic Obstructive Pulmonary Disease Case with Regentime® Procedure. EPRA International Journal of Research and Development (IJRD). 2022;7(7):57-60.
36. Avdeev S, Aisanov Z, Arkhipov V, Belevskiy A, Vizel A, Demko I, et al. Inhaled corticosteroids administration/withdrawal as a therapeutic continuum for patients with chronic obstructive pulmonary disease in real clinical practice. PULMONOLOGIYA. 2023;33(1):109-18.
37. Cazzola M, Rogliani P, Calzetta L, Ora J, Matera MG. A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. Expert Review of Clinical Pharmacology. 2022;15(3):269-83.
38. Gong Y, Lin C, Jin Y, Chen R. The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease. Canadian Respiratory Journal. 2022;2022:2878648.
39. Hess MW. Oxygen Therapy in COPD. Respiratory Care. 2023;68(7):998-1012.
40. Hoang T, Anderson J, Hay K, Tay G. EVALUATION OF INPATIENT OXYGEN THERAPY IN HYPERCAPNIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). Respirology. 2019;24:124-.
41. Alshabani K, Stoller JK. A Review of Long-term Oxygen Therapy in Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine. 2018;25(1):1-6.
42. Jeyachandran V, Hurst JR. Advances in chronic obstructive pulmonary disease: management of exacerbations. British Journal of Hospital Medicine. 2022;83(7):1-7.
43. Костинов М, Протасов А, Жестков А, Штейнер М, Тезиков Ю, Липатов И. Влияние разных схем вакцинации против пневмококковой инфекции на клиническое течение хронической обструктивной болезни легких: фокус на изменении микробиоценоза мокроты. Туберкулез и болезни легких. 2021;99(7):7-17.
44. Dean RH. Respiratory Care Management of COPD Exacerbations. Respiratory Care. 2023;68(6):821.
45. Tran XB, Tran TT, Bui SN, Le Thi L. A Survey of Antibiotic Usage Characteristics in Treatment of Acute Exacerbation of COPD Patients in National Hospital 74. VNU Journal of Science: Medical and Pharmaceutical Sciences. 2022;38(2).
46. Higham A, Scott T, Li J, Gaskell R, Dikwa AB, Shah R, et al. Effects of corticosteroids on COPD lung macrophage phenotype and function. Clinical science. 2020;134(7):751-63.
47. Königsdorfer N, Jörres RA, Söhler S, Welte T, Behr J, Ficker JH, et al. Adherence to respiratory and nonrespiratory medication in patients with COPD: results of the German COSYCONET cohort. Patient preference and adherence. 2019:1711-21.
48. Criner GJ. Surgical and Interventional Approaches in COPD. Respiratory Care. 2023;68(7):939-60.
49. Ashraf O, Disilvio B, Young M, Ghosh S, Cheema T. Surgical Interventions for COPD. Critical Care Nursing Quarterly. 2021;44(1).
50. Vora S, Shah C. COPD classification using machine learning algorithms. Int Res J Eng Technol. 2019;6:608-11.
51. Cope GF. Current treatments for chronic obstructive pulmonary disease (COPD). British Journal of Healthcare Management. 2014;20(8):372-8.